Insulin-like growth factor type I receptor: A new target in the treatment of non-small cell lung cancer patients

Memo - Magazine of European Medical Oncology

Volumn 3, Issue 2, 2010, Pages 81-84

  Heller, G ^a   Zochbauer Muller S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

CP 751,871; IGF IR; NSCLC

Indexed keywords

CARBOPLATIN; CP 751871; ERLOTINIB; GAMMA GLUTAMYLTRANSFERASE; INSULIN; ORAL ANTIDIABETIC AGENT; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUNG SURGERY; MALIGNANT TRANSFORMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; THROMBOCYTOPENIA;

EID: 77956158984     PISSN: 18655041     EISSN: 18655076     Source Type: Journal    
DOI: 10.1007/s12254-010-0192-9     Document Type: Review

References (26)

1. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev, 16(1): 3-34, 1995.
2. Ryan PD, Goss PE. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist, 13(1): 16-24, 2008.
3. Clemmons DR. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol, 140(1-2): 19-24, 1998.
4. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst, 92(18): 1472-1489, 2000.
5. Giorgetti S, Ballotti R, Kowalski-Chauvel A, Tartare S, Van Obberghen E. The insulin and insulin-like growth factor-I receptor substrate IRS-1 associates with and activates phosphatidylinositol 3-kinase in vitro. J Biol Chem, 268(10): 7358-7364, 1993.
6. Hermanto U, Zong CS, Wang LH. Inhibition of mitogen-activated protein kinase kinase selectively inhibits cell proliferation in human breast cancer cells displaying enhanced insulin-like growth factor Imediated mitogen-activated protein kinase activation. Cell Growth Differ, 11(12): 655-664, 2000.
7. Grey A, Chen Q, Xu X, Callon K, Cornish J. Parallel phosphatidylinositol- 3 kinase and p42/44 mitogen-activated protein kinase signaling pathways subserve the mitogenic and antiapoptotic actions of insulin-like growth factor I in osteoblastic cells. Endocrinology, 144(11): 4886-4893, 2003.
8. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res, 53(5): 1102-1106, 1993.
9. LeRoith D, Baserga R, Helman L, Roberts CT Jr. Insulin-like growth factors and cancer. Ann Intern Med, 122(1): 54-59, 1995.
10. Neuenschwander S, Roberts CT Jr, LeRoith D. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocrinology, 136(10): 4298-4303, 1995.
11. Jiang Y, Rom WN, Yie TA, Chi CX, Tchou-Wong KM. Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor. Oncogene, 18(44): 6071-6077, 1999.
12. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst, 91(2): 151-156, 1999.
13. Wu X, Yu H, Amos CI, Hong WK, Spitz MR. Joint effect of insulinlike growth factors and mutagen sensitivity in lung cancer risk. J Natl Cancer Inst, 92(9): 737-743, 2000. (Pubitemid 30365534)
14. Kim WY, Jin Q, Oh SH, Kim ES, Yang YJ, Lee DH, et al. Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development. Cancer Res, 69(18): 7439-7448, 2009.
15. Ludovini V, Bellezza G, Pistola L, Bianconi F, Di Carlo L, Sidoni A, et al. High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol, 20(5): 842-849, 2009.
16. Cappuzzo F, Toschi L, Tallini G, Ceresoli GL, Domenichini I, Bartolini S, et al. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann Oncol, 17(7): 1120-1127, 2006.
17. Cappuzzo F, Tallini G, Finocchiaro G, Wilson RS, Ligorio C, Giordano L, et al. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Ann Oncol, 21(3): 562-567, 2010.
18. Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Szymanowska A, et al. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-smallcell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol, 28(13): 2174-2180, 2010.
19. Lee HY, Chun KH, Liu B, Wiehle SA, Cristiano RJ, Hong WK, et al. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Res, 62(12): 3530-3537, 2002.
20. Hofmann F, Garcia-Echeverria C. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov Today, 10(15): 1041-1047, 2005.
21. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res, 11(5): 2063-2073, 2005.
22. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res, 13(19): 5834-5840, 2007.
23. Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, Yin D, et al. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol, 4(11): 1397-1403, 2009.
24. Iwasa T, Okamoto I, Suzuki M, Hatashita E, Yamada Y, Fukuoka M, et al. Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells. Clin Cancer Res, 15(16): 5117-5125, 2009.
25. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol, 27(15): 2516-2522, 2009.
26. Lee CY, Jeon JH, Kim HJ, Shin DH, Roh TW, Ahn CM, et al. Clinical significance of insulin-like growth factor-1 receptor expression in stage I non-small-cell lung cancer: immunohistochemical analysis. Korean J Intern Med, 23(3): 116-120, 2008.